The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial
A Randomized, Double-Blind, Double-Dummy, Parallel Group, Factorial Design Trial to Assess the Efficacy and Safety of up to Six Weeks Treatment With 20mg, 40mg, or 80mg QD Doses of Carvedilol Controlled Release Formulation (COREG CR) or 10mg, 20mg, or 40mg QD Doses of Lisinopril (Zestril) or a Combination of One of the Doses of Each Medication
Sponsor: GlaxoSmithKline
Listed as NCT00347360, this PHASE3 trial focuses on Hypertension and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jul 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albuquerque, United States, Ames, United States, Anniston, United States, Arlington, United States, Asheville, United States, Aurora, United States, Austin, United States, Avon, United States, Beaufort, United States, Beaver, United States and 123 more location s